PERRIGO COMPANY PLC (PRGO): Modelo de negócios Canvas [Jan-2025 Atualizado]

No cenário dinâmico da inovação farmacêutica, a Perrigo Company PLC (PRGO) surge como uma potência estratégica, transformando a acessibilidade da saúde por meio de seu modelo de negócios meticulosamente criado. Ao misturar perfeitamente a produção de medicamentos genéricos, a pesquisa farmacêutica especializada e as soluções econômicas, a Perrigo se posicionou como um participante crítico na entrega de cuidados de saúde acessíveis nos mercados globais. Sua abordagem abrangente não apenas atende às diversas necessidades do cliente, mas também desafia os paradigmas farmacêuticos tradicionais, tornando a assistência médica mais atingível e adaptável para pacientes, provedores e redes de seguros.

PERRIGO COMPANY PLC (PRGO) - Modelo de negócios: Parcerias -chave

Fabricantes farmacêuticos e parceiros de desenvolvimento de contratos

A Perrigo colabora com vários parceiros de fabricação farmacêutica para apoiar seu portfólio diversificado de produtos.

Tipo de parceiro	Número de parcerias ativas	Valor estimado de colaboração anual
Organizações de fabricação contratadas	12	US $ 287 milhões
Parceiros de Desenvolvimento de Contratos	7	US $ 156 milhões

Cadeias e distribuidores de farmácias de varejo

Perrigo mantém relacionamentos estratégicos com as principais redes de farmácias e canais de distribuição.

• CVS Health Corporation
• Aliança Walgreens Boots
• Walmart Inc.
• RITE AID CORPORATION

Distribuidor	Volume anual de vendas	Duração do contrato
CVS Health	US $ 423 milhões	Contrato de 3 anos
Walgreens	US $ 392 milhões	Contrato de 5 anos

Fornecedores de drogas genéricos e fornecedores de matéria -prima

Perrigo fontes de matérias -primas de fornecedores globais de ingredientes farmacêuticos.

Região do fornecedor	Valor anual de compras	Categorias de materiais primários
China	US $ 214 milhões	Ingredientes farmacêuticos ativos
Índia	US $ 187 milhões	Componentes de medicamentos genéricos

Provedores de seguros de saúde

A Perrigo colabora com as principais redes de seguros de saúde para apoiar a distribuição e o reembolso de produtos.

• Grupo UnitedHealth
• Anthem Inc.
• Humana Inc.

Instituições de pesquisa e centros médicos acadêmicos

Perrigo mantém parcerias de pesquisa com instituições acadêmicas para o desenvolvimento de produtos.

Instituição	Foco na pesquisa	Investimento anual de pesquisa
Universidade Johns Hopkins	Inovação farmacêutica	US $ 4,2 milhões
Stanford Medical Center	Ensaios clínicos	US $ 3,7 milhões

PERRIGO COMPANY PLC (PRGO) - Modelo de negócios: Atividades -chave

Desenvolvimento e fabricação de produtos farmacêuticos

Investimento anual de P&D: US $ 205,4 milhões em 2022

Instalações de fabricação	Localização	Especialização
Dublin, Irlanda	Sede global	Fabricação farmacêutica
Allegan, Michigan	Estados Unidos	OTC e produção de medicamentos genéricos

Produção de medicamentos genéricos e sem receita

Portfólio de produtos genéricos totais: 112 linhas de produtos

• Participação de mercado de medicamentos OTC: 3,7%
• Ofertações totais de produtos OTC: 84 produtos distintos

Pesquisa farmacêutica especializada

Áreas de foco de pesquisa: dermatologia, respiração, atendimento pediátrico

Categoria de pesquisa	Programas de pesquisa ativa	Investimento
Dermatologia	7 programas ativos	US $ 62,1 milhões
Cuidado pediátrico	5 programas ativos	US $ 41,3 milhões

Controle de qualidade e conformidade regulatória

Orçamento de conformidade regulatória: US $ 48,3 milhões em 2022

• Taxa de sucesso da inspeção da FDA: 98,6%
• Pessoal de controle de qualidade: 276 profissionais

Expansão e distribuição do mercado global

Presença do mercado internacional: 17 países

Região	Centros de distribuição	Receita anual
América do Norte	6 centros	US $ 4,2 bilhões
Europa	4 centros	US $ 1,7 bilhão

PERRIGO COMPANY PLC (PRGO) - Modelo de negócios: Recursos -chave

Instalações de fabricação avançadas

A Perrigo opera várias instalações de fabricação globalmente, com locais importantes, incluindo:

Localização	Tipo de instalação	Capacidade de fabricação
Dublin, Irlanda	Sede global	Várias linhas de produção
Allegan, Michigan, EUA	Fabricação primária de OTC	Mais de 15 instalações de produção
Israel	Fabricação farmacêutica	3 grandes sites de produção

Capacidades de pesquisa e desenvolvimento farmacêuticos

O investimento e os recursos de P&D da Perrigo incluem:

• Despesas anuais de P&D: US $ 187,4 milhões (ano fiscal de 2022)
• Centros de pesquisa localizados em vários países
• Mais de 500 cientistas e engenheiros de pesquisa ativa

Portfólio de propriedade intelectual

Métricas principais de propriedade intelectual:

Categoria IP	Número
Patentes ativas	276
Pedidos de patente pendentes	124
Registros de marca registrada	Mais de 350

Força de trabalho científica e técnica qualificada

Composição da força de trabalho:

• Total de funcionários: 4.900 (a partir de 2022)
• Funcionários com diplomas avançados: 32%
• Distribuição global da força de trabalho em 13 países

Sistemas de garantia de qualidade

Recursos de gerenciamento da qualidade:

• Instalações de fabricação registradas pela FDA
• ISO 9001: 2015 Sistemas de gerenciamento de qualidade certificados
• Infraestrutura de monitoramento de conformidade contínua

PERRIGO COMPANY PLC (PRGO) - Modelo de negócios: proposições de valor

Soluções de saúde acessíveis

A Perrigo registrou vendas líquidas de US $ 4,41 bilhões em 2023, com foco no fornecimento de soluções de saúde econômicas em vários segmentos de mercado.

Categoria de produto	Segmento de mercado	Economia média de custos
Medicamentos genéricos	Medicamentos prescritos	40-60% menor do que as alternativas de marca
Medicamentos sem receita	Assistência médica ao consumidor	25-45% de redução de custo

Medicamentos genéricos e de marca de alta qualidade

Perrigo mantém Instalações de fabricação aprovadas pela FDA com padrões estritos de controle de qualidade.

• Investimento total de P&D em 2023: US $ 205 milhões
• Número de locais de fabricação aprovados pela FDA: 15
• Taxa de conformidade da qualidade: 99,7%

Ampla gama de ofertas de produtos farmacêuticos

Categoria de produto	Número de produtos	Cobertura de mercado
Genéricos da prescrição	350+ skus	América do Norte, Europa
Medicamentos OTC	250+ skus	Mercados globais
Assistência médica ao consumidor	Mais de 200 skus	Varejo, canais de farmácia

Alternativa econômica aos produtos farmacêuticos de marca

O portfólio genérico de produtos genéricos da Perrigo fornece uma economia média de custos de 52% em comparação com os medicamentos da marca.

• Preço médio do medicamento genérico: US $ 15 a US $ 30 por receita
• Medicação de marca equivalente: US $ 75- $ 150 por receita
• Economia anual de custos para pacientes: estimado US $ 3,2 bilhões

Desenvolvimento inovador de produtos de saúde

A Perrigo investiu US $ 205 milhões em P&D durante 2023, com foco em soluções inovadoras de saúde.

Área de inovação	Aplicações de patentes	Novos lançamentos de produtos
Formulações farmacêuticas	37	22
Tecnologias de administração de medicamentos	15	8

PERRIGO COMPANY PLC (PRGO) - Modelo de negócios: Relacionamentos do cliente

Suporte de vendas diretas para profissionais de saúde

Perrigo mantém uma força de vendas dedicada de 562 representantes profissionais direcionados a prestadores de serviços de saúde, farmácias e instituições médicas a partir de 2023.

Categoria representativa de vendas	Número de representantes	Segmento de destino
Representantes de vendas farmacêuticas	362	Hospitais e clínicas
Representantes de vendas de produtos OTC	200	Farmácias de varejo

Plataformas de atendimento ao cliente online

A Perrigo opera uma infraestrutura abrangente de suporte ao cliente digital com as seguintes métricas:

• Portal de suporte on -line 24/7
• Tempo médio de resposta digital: 2,7 horas
• Plataforma de atendimento ao cliente responsiva para dispositivos móveis

Programas de assistência ao paciente

Perrigo oferece programas estruturados de apoio ao paciente com a seguinte cobertura:

Tipo de programa	Beneficiários anuais	Intervalo de apoio financeiro
Assistência prescrita	47.500 pacientes	$ 50- $ 5.000 por paciente
Suporte genérico de medicamentos	92.300 pacientes	US $ 25 a US $ 3.500 por paciente

Suporte técnico para produtos farmacêuticos

A infraestrutura de suporte técnico inclui:

• Helpline técnica farmacêutica dedicada
• 3 centros de suporte regionais
• Tempo médio de resolução de consulta técnica: 4,2 horas

Estratégias de envolvimento do cliente responsivas

As métricas de engajamento de clientes da Perrigo demonstram uma abordagem robusta:

Canal de engajamento	Volume anual de interação	Taxa de satisfação do cliente
Suporte telefônico	218.600 interações	87.3%
Suporte por e -mail	156.400 interações	84.6%
Suporte de bate -papo digital	95.300 interações	82.1%

PERRIGO COMPANY PLC (PRGO) - Modelo de negócios: canais

Distribuidores por atacado farmacêuticos

Perrigo distribui através dos principais atacadistas farmacêuticos com a seguinte penetração no mercado:

Atacadista	Quota de mercado	Volume anual de distribuição
Amerisourcebergen	27.3%	US $ 3,2 bilhões
McKesson Corporation	23.5%	US $ 2,8 bilhões
Cardinal Health	19.7%	US $ 2,4 bilhões

Redes de farmácias de varejo

A distribuição de canais de farmácia de varejo da Perrigo inclui:

• CVS Health: 35% da rede de varejo
• Aliança Walgreens Boots: 28% da rede de varejo
• Walmart: 15% da rede de varejo
• Rite Aid: 12% da rede de varejo

Plataformas on-line direta ao consumidor

Métricas de canal de vendas on -line:

Plataforma	Receita anual	Taxa de crescimento
Site da empresa	US $ 124 milhões	8.3%
Amazon Marketplace	US $ 87 milhões	12.5%

Representantes de vendas de provedores de saúde

Métricas da Força de Vendas:

• Total de Representantes de Vendas: 287
• Vendas médias por representante: US $ 1,3 milhão anualmente
• Cobertura geográfica: 48 estados

Cadeias de suprimentos médicos internacionais

Distribuição Internacional Distribuição:

Região	Receita anual	Penetração de mercado
Europa	US $ 412 milhões	22%
Canadá	US $ 276 milhões	15%
Ásia -Pacífico	US $ 189 milhões	10%

PERRIGO COMPANY PLC (PRGO) - Modelo de negócios: segmentos de clientes

Farmácias de varejo

Perrigo atende a aproximadamente 60.000 locais de farmácias de varejo nos Estados Unidos, incluindo grandes redes como CVS, Walgreens e Walmart.

Tipo de farmácia de varejo	Penetração de mercado	Volume anual de vendas
Cadeias de farmácias nacionais	85%	US $ 1,2 bilhão
Farmácias independentes	15%	US $ 240 milhões

Sistemas hospitalares

A Perrigo fornece mais de 3.500 sistemas hospitalares com produtos farmacêuticos genéricos e de marca.

• Volume de compra hospitalar: US $ 450 milhões anualmente
• Categorias de produtos: medicamentos sem receita, medicamentos genéricos de prescrição
• Cobertura do sistema hospitalar: 68% dos hospitais dos EUA

Provedores de seguros de saúde

A Perrigo faz parceria com 25 principais provedores de seguros de saúde em todo o país.

Categoria de provedor de seguros	Valor anual do contrato	Número de provedores
Seguradoras nacionais	US $ 680 milhões	12
Seguradoras regionais	US $ 210 milhões	13

Pacientes individuais

Perrigo atinge aproximadamente 45 milhões de pacientes individuais anualmente através de vários canais de produtos.

• Vendas de produtos diretas ao consumidor: US $ 320 milhões
• Demografia de consumo primário: idades de 25 a 65
• Acessibilidade ao produto: plataformas de varejo online e na loja

Organizações de saúde do governo

A Perrigo fornece produtos farmacêuticos para programas de saúde federal e estadual.

Segmento do governo	Valor anual do contrato	Categorias de produtos
Programas Medicaid	US $ 290 milhões	Medicamentos genéricos
Assuntos dos Veteranos	US $ 180 milhões	Medicamentos prescritos e OTC

PERRIGO COMPANY PLC (PRGO) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Perrigo Company Plc registrou despesas de P&D de US $ 157,4 milhões.

Ano fiscal	Despesas de P&D	Porcentagem de receita
2023	US $ 157,4 milhões	3.7%
2022	US $ 146,3 milhões	3.5%

Custos de fabricação e produção

O custo total de mercadorias da Perrigo foi vendido para 2023 foi de US $ 3,089 bilhões.

• Instalações de fabricação: 17 sites globais
• Força de trabalho de fabricação total: aproximadamente 4.500 funcionários
• Capacidade anual de produção: mais de 70 bilhões de unidades

Investimentos de conformidade regulatória

As despesas relacionadas à conformidade em 2023 totalizaram aproximadamente US $ 45,2 milhões.

Despesas de marketing e vendas

Ano fiscal	Despesas de marketing	Despesas de vendas	Total
2023	US $ 312,6 milhões	US $ 228,4 milhões	US $ 541 milhões

Infraestrutura de distribuição global

• Total de logística e custos de distribuição: US $ 213,7 milhões em 2023
• Centros de distribuição: 8 locais globais primários
• Volume anual de envio: mais de 40 milhões de pacotes

Despesas operacionais totais para Perrigo em 2023: US $ 4,242 bilhões

PERRIGO COMPANY PLC (PRGO) - Modelo de negócios: fluxos de receita

Vendas genéricas de medicamentos

No ano fiscal de 2022, o segmento farmacêutico genérico de Perrigo gerou US $ 1,16 bilhão em receita.

Categoria de produto	Receita anual	Quota de mercado
Medicamentos genéricos prescritos	US $ 872 milhões	7.2%
Farmacêuticos do Hospital Genérico	US $ 288 milhões	4.5%

Produtos farmacêuticos sem receita

O segmento de OTC da Perrigo registrou US $ 2,03 bilhões em receita para 2022.

• Receita do segmento de saúde do consumidor: US $ 1,45 bilhão
• Linha de produtos de autocuidado: US $ 580 milhões

Ofertas farmacêuticas especiais de marca

A marca Specialty Pharmaceuticals gerou US $ 456 milhões em 2022.

Categoria de produto especializado	Receita anual
Produtos de dermatologia	US $ 212 milhões
Medicamentos prescritos especializados	US $ 244 milhões

Distribuição do mercado internacional

A receita internacional para Perrigo em 2022 totalizou US $ 687 milhões.

• Receita do mercado europeu: US $ 392 milhões
• Receita do mercado da Ásia-Pacífico: US $ 185 milhões
• Receita do mercado latino -americano: US $ 110 milhões

Serviços de fabricação contratados

A receita de fabricação contratada atingiu US $ 214 milhões em 2022.

Tipo de serviço de fabricação	Receita anual
Fabricação farmacêutica	US $ 156 milhões
Fabricação nutracêutica	US $ 58 milhões

Perrigo Company plc (PRGO) - Canvas Business Model: Value Propositions

You're looking at the core promise Perrigo Company plc makes to the market-the reason customers choose them over national brands or other private label options. Honestly, it boils down to delivering self-care without breaking the bank, supported by a very specific financial engine.

Quality, affordable self-care products across all price points

Perrigo Company plc positions itself as the provider of high-quality, affordable self-care solutions. This isn't just a slogan; the numbers show where the focus is. The company estimates it saves its consumers approximately $7.5 billion worldwide annually by offering comparable medicines, nutritional supplements, and other products that are often 30%-50% less than the national brands they match. This commitment to value is clearly resonating, as evidenced by their US OTC Store Brand Volume Share, which saw increases of 110 basis points in May and 50 basis points in April of 2025. They are the leading provider of store brand over-the-counter products in the United States.

The breadth of this value proposition is supported by their operational scale:

• The business model includes over 100+ molecules.
• This portfolio covers 100% price point coverage across the market.
• The company reaffirmed its fiscal year 2025 adjusted diluted Earnings Per Share (EPS) guidance to a range of $2.90 to $3.10, which represents a projected growth of 13% to 21% over the prior year.

Dual model: cash-generative store brands fund high-growth brands

Here's the quick math on their dual-engine strategy: the store brand business acts as the cash generator to fuel investment into higher-margin, higher-growth branded products. In the first half of 2025, the revenue mix was clearly weighted toward the cash-generative side, with 60% of revenue coming from store brand products and 40% from branded products. This structure is designed to deliver stable performance. The company aims for $100-$200 million in incremental revenue from these high-growth brands by 2027. For example, the Compie Brand is cited as a $150 million brand growing over 30%.

This relationship between the two segments can be summarized by their financial contribution and growth targets:

Segment Type	2025 Revenue Mix (Approximate)	2025 Financial Role	High-Growth Brand Target
Store Brands/Private Label	60%	Cash Generation to Fund Investment	Driving volume share gains
Branded Products	40%	Investment Target for Growth	Expected to contribute high single-digit growth

Accessibility to self-care solutions without a prescription

Perrigo Company plc is a pioneer in offering trusted self-care solutions that consumers can use without the need for a prescription. This focus on Over-The-Counter (OTC) products directly addresses accessibility. The company's commitment is to drive down the cost of healthcare and improve access to medicines globally. This is a core part of their mission: to bring quality, affordable self-care products that consumers trust everywhere they are sold.

Broad portfolio coverage of 100% consumer price point coverage

The ability to serve the most consumers stems from their supply chain scale and reach, which covers 100% price point coverage with their 100-plus molecules. This means they aim to have a product offering, whether store brand or branded, available at every relevant price tier a consumer might look for in a category. This extensive coverage, combined with significant U.S.-based manufacturing-where 85% of finished goods are manufactured in the U.S.-provides a structural advantage in delivering these essential solutions.

The company's Q3 2025 adjusted operating margin was 16.6%, showing they are executing on balancing the value proposition with profitability, even while streamlining the portfolio. Finance: draft 13-week cash view by Friday.

Perrigo Company plc (PRGO) - Canvas Business Model: Customer Relationships

Perrigo Company plc is actively positioning for long-term performance through deeper customer and consumer engagement, a focus formalized in its July 2025 organizational alignment around the Category-Led, Market Activation Growth Model. Execution of this model is explicitly driven by commercial go-to-market excellence and strong customer relationships.

Strong, long-term customer partnerships with major retailers

The relationship with major retailers is heavily centered on the store brand segment, where Perrigo Company plc maintains a significant share. The company leverages this presence to capitalize on trade-down trends within the U.S. market. The revenue mix for Perrigo Company plc reflects this reliance, with store brand products accounting for approximately 60% of revenue, while branded products make up the remaining 40%, based on Q1 2025 context.

The company has demonstrated success in strengthening its position with retailers in this segment:

• U.S. Store Brand Service levels were reported back to over 90% as of June 2025.
• U.S. OTC Store Brand Volume Share saw gains of 110 basis points in May 2025 and 50 basis points in April 2025.
• The organic net sales for Q1 2025 reflected a previously disclosed net lost distribution of lower margin products in U.S. Store Brand of 0.8%.

Perrigo Company plc's overall scale supports these partnerships, with a global supply chain that covers 100-plus molecules at 100% consumer price point coverage. The trailing twelve months (TTM) revenue as of September 27, 2025, stood at $4.28 Billion USD.

Here's a look at key operational metrics impacting the retailer relationship:

Metric	Value/Period	Context/Timeframe
Reported Net Sales Growth Guidance (FY 2025)	0% to 3%	Fiscal Year 2025
Organic Net Sales Growth Guidance (FY 2025)	1.5% to 4.5%	Fiscal Year 2025
Adjusted Diluted EPS Range (FY 2025)	$2.90 to $3.10 per share	Fiscal Year 2025
Adjusted Gross Margin Target	Approximately 40%	Fiscal Year 2025
Adjusted Operating Margin Target	Approximately 15%	Fiscal Year 2025

Consumer-led engagement and demand generation

Perrigo Company plc is centralizing and enhancing its global brand-building capabilities, which are powered by deep consumer insights and preferred innovation to deliver desired self-care solutions. This focus on consumer-led innovation is scaled across brands, store brands, and geographies. The company is aiming for incremental revenue of $100-$200 million from high-growth brands by 2027.

The strategy includes specific brand performance metrics:

• The Compie Brand is reported as growing over 30%.
• The Moderna Brand saw net sales increase by over 35%.
• Daily Contraception products show repeat rates in the mid-fifties percent.

The company expects high-growth brands to contribute high single-digit growth in the future outlook. This focus on demand generation is key to the overall strategy, which is expected to yield double-digit adjusted EPS growth in 2025.

Dedicated commercial go-to-market excellence teams

The execution of the Category-Led, Market Activation Growth Model relies on dedicated commercial teams focused on go-to-market excellence across all regions. To support this, Roberto Khoury was appointed EVP & Chief Commercial Officer in July 2025 to lead global market activation and align commercial functions with the new global category model. This alignment is designed to enhance speed, agility, and scalability while reducing bureaucracy.

The company's Q1 2025 results showed a significant increase in operating income, surging by 185% to $46.9 million, partially driven by reduced operating expenses. Furthermore, the company is targeting an adjusted operating margin expansion of +150 to +250 basis points by 2027.

Perrigo Company plc (PRGO) - Canvas Business Model: Channels

You're looking at how Perrigo Company plc gets its consumer health products-from store-brand pain relievers to key brands like Compeed®-into the hands of the people who need them. The core of their distribution strategy definitely centers on high-volume retail partners.

Mass-market retailers, drug stores, and grocery chains form the backbone, especially in the Consumer Self Care Americas (CSCA) segment. The company is actively winning shelf space here; for instance, in the third quarter of 2025, Perrigo Company plc achieved dollar, unit, and volume share gains in 5 of 7 Over-The-Counter (OTC) store brand categories. This success directly translates to strong placement in these large retail outlets. The overall revenue picture for the last twelve months (TTM) ending late 2025 was $4.28 Billion USD, showing the scale of this channel dependency.

Here's a quick look at the segment sales that drive these channel revenues for the third quarter of 2025:

Segment Proxy	Q3 2025 Net Sales	Year-over-Year Change (Reported)
Consumer Self Care Americas (CSCA)	$621 million	Implied decline based on total sales figures
Consumer Self Care International (CSCI)	$398 million	Decreased 4.5%

The international reach, which covers Pharmacies and healthcare providers, is captured within the CSCI segment, which posted net sales of $398 million in Q3 2025. Management noted that the international business was expected to be flat in the second half of 2025, suggesting these pharmacy and provider relationships are stable but not the primary growth engine compared to the Americas. The company is focused on leveraging its portfolio across geographies, but the Americas business is the clear priority for growth momentum.

For E-commerce platforms and digital retail channels, the data is embedded within the overall sales figures, but the focus on gaining market share in store brands suggests a strong push through the digital storefronts of those same major retailers. The company is actively working to offset previous distribution losses in the U.S. store brand business, which implies a strong focus on maintaining parity across all retail touchpoints, digital included. The overall organic net sales decline in Q3 2025 was -4.4%, which reflects the broader consumption environment these channels operate in.

Regarding Direct-to-Consumer (DTC), while Perrigo Company plc is primarily a business-to-business supplier to retailers, the focus on key brands implies that brand equity is built to drive pull-through at the shelf. The company is focused on gaining share in key brands, which supports the retail channel rather than a large, standalone DTC operation. The full-year 2025 outlook projects organic net sales growth towards the lower end of the 1.5% to 4.5% target range, which is the ultimate measure of channel effectiveness.

• Store brand market share gains in 5 of 7 OTC categories (Q3 2025).
• CSCA segment sales were $621 million in Q1 2025.
• CSCI segment sales were $398 million in Q3 2025.
• Full Year 2025 Net Sales Growth Outlook: -2.5% to -3.0%.
• The company is aiming for Adjusted EPS between $2.70 and $2.80 for Fiscal Year 2025.

Perrigo Company plc (PRGO) - Canvas Business Model: Customer Segments

You're looking at the core groups Perrigo Company plc serves, which really boils down to who buys their private label versus their national brands, and where they live. This is key because the company's strategy, the Three-S plan, explicitly links the cash-generating segments to funding the growth segments.

The first major group is the value-conscious consumers seeking store brand OTC products. This is the bedrock of the Consumer Self-Care Americas (CSCA) segment. Perrigo Company plc is the only large-scale U.S. store brand and contract manufacturer for many self-care items. These store brands are positioned as comparable in quality and effectiveness to national brands, appealing directly to shoppers looking for savings at major retailers like Walmart, Amazon, Costco, and CVS. Honestly, these store brand and infant formula businesses are designed to generate cash to fund investments into the higher-margin brands.

Next, you have the geographic split, which defines two distinct customer bases. Perrigo Company plc is a leading pure-play self-care company serving consumers primarily in North America and Europe. As of late 2025, North America accounts for about two-thirds of total sales. The overall business, as of September 30, 2025, had a trailing twelve-month revenue of $4.28 billion. The customer base is split between the two main operating segments:

Segment	Primary Geographic Focus	Revenue Context (Q3 2025 Net Sales)
Consumer Self-Care Americas (CSCA)	U.S. and Canada	Reported Net Sales of $646 million (Q3 2025)
Consumer Self-Care International (CSCI)	Primarily Europe and Australia	Reported Net Sales of $434 million (Q2 2025)

Then there are the parents and caregivers of infants. This group is served by the Nutrition category, which is dominated by the infant formula business. This segment is expected to generate approximately $360 million in net sales for 2025. To put that in perspective, that's less than 10% of the company's estimated annual net sales of $4.3 billion for 2025. Because the external environment has shifted, Perrigo Company plc is currently conducting a strategic review of this business, which includes reassessing a previously announced $240 million investment.

Finally, you have the customers seeking specialized, higher-margin self-care brands. These consumers are the target for the 'High-Grow' brands that Perrigo Company plc prioritizes investment in. In the CSCI segment, which focuses outside the U.S. and Canada, revenue generation is primarily through these national brands, such as Compeed®, Solpadeine®, and ellaOne®. These are the areas management is strengthening to drive better returns, contrasting with the cash-generating store brand business.

Finance: draft 13-week cash view by Friday.

Perrigo Company plc (PRGO) - Canvas Business Model: Cost Structure

You're looking at the hard numbers driving Perrigo Company plc's operational expenses as of late 2025. This structure is heavily influenced by manufacturing scale, ongoing efficiency programs, and necessary innovation spending.

The cost of goods sold (COGS) remains a major component, reflecting the scale of manufacturing and supply chain complexity in the consumer self-care space. For the fiscal quarter ending June 2025, the reported Cost of Sales was $666.2 million. This is reflected in the reported gross margin for the second quarter of 2025, which stood at 26.2%, with an adjusted gross margin of 28.2%. To be fair, the company is also managing potential external cost shocks; Perrigo estimated a gross increase to global COGS in 2025, beginning in the fourth quarter, of approximately $10 million to $20 million, with a full-year impact around $50 million to $60 million, potentially due to pharmaceutical tariffs.

A significant part of the current cost management focus is Project Energize, an efficiency program launched in the first quarter of 2024. This initiative is designed to reset the SG&A operating expense base and drive organizational agility. As of the second quarter of 2025, Project Energize had achieved gross annual savings of approximately $159 million since its inception, with $27 million reinvested. The program is expected to deliver total annualized pre-tax savings in the range of $140 million to $170 million by the end of 2026, with $40 million to $60 million of those savings expected to be reinvested. The associated restructuring and related charges are estimated to total between $140 million to $160 million through 2026, which includes $20 million to $40 million earmarked for capability enhancement investments.

Investment in Research and development (R&D) is necessary to fuel consumer-led innovation and maintain brand relevance. You can see the impact on operating expenses; for instance, in the second quarter of 2025, lower R&D investments provided a partial offset to the decrease in Adjusted Operating Income, alongside lower advertising and promotional (A&P) spend and Project Energize benefits. This shows a balancing act between cost discipline and necessary spending on future growth drivers like Opill® and other brand activations.

Finally, the balance sheet reflects substantial financial obligations that impact financing costs. Perrigo Company plc reported total debt of $3.65 billion as of June 28, 2025. This debt level results in an interest coverage ratio of 2.5x, with total debt at $3.65B against total assets of $10.08B. Lower interest expense from reduced debt was a positive driver for Adjusted EPS in the second quarter of 2025.

Here's a quick look at some key financial metrics impacting the cost base as of the end of Q2 2025:

Financial Metric	Amount/Value (as of June 28, 2025)
Total Debt	$3.65 billion
Cash and Cash Equivalents	$454 million
Reported Gross Margin (Q2 2025)	26.2%
Adjusted Gross Margin (Q2 2025)	28.2%
Project Energize Gross Annual Savings Achieved (to Q2 2025)	$159 million
Project Energize Reinvestment (to Q2 2025)	$27 million
Estimated Total Restructuring Charges for Project Energize	$140 million to $160 million

The ongoing commitment to Project Energize savings, alongside the management of COGS pressures and strategic R&D allocation, defines the near-term cost structure for Perrigo Company plc. Finance: draft 13-week cash view by Friday.

Perrigo Company plc (PRGO) - Canvas Business Model: Revenue Streams

Perrigo Company plc generates its revenue primarily through the sale of its Consumer Self-Care products across two main operating segments. The financial performance for the third quarter of fiscal year 2025 provides a clear snapshot of the current revenue contribution by geography.

For the third quarter of 2025, total reported net sales for Perrigo Company plc were $1,043.3 million. Year-to-date net sales through the first nine months of 2025 reached $3,143.5 million.

The segment breakdown for the third quarter of 2025 net sales is as follows:

Revenue Stream Component	Q3 2025 Net Sales Amount
Net sales from Consumer Self-Care Americas (CSCA) segment	$646 million
Net sales from Consumer Self-Care International (CSCI) segment	$398 million

The composition of the revenue mix leans heavily on private label offerings, though specific 2025 segment sales figures for private label versus branded are not explicitly broken out in the latest reports, a June 2025 presentation indicated the following revenue split:

Revenue Type	Approximate Revenue Mix (as of June 2025)
Sales of store brand/private label OTC products	60%
Sales of national/High-Grow brands	40%

Within the national/High-Grow brands category, specific products show significant momentum. For instance, the Mederma® brand (referred to as the Moderna Brand in one source) saw its net sales increase by over 35%. Conversely, the impact of the Opill® launch stocking benefit in the prior year resulted in a -0.5% drag on year-to-date 2025 organic net sales.

Perrigo Company plc has updated its expectations for the full fiscal year 2025, factoring in industry dynamics and consumption trends. The projection for the full-year 2025 net sales growth is set between -2.5% to -3.0%.

The Infant Formula business, which is currently undergoing a strategic review, was expected to generate approximately $360 million in net sales for the full year 2025, representing less than 10% of the Company's total annual net sales.

The company is focused on driving growth through its key brands, with management aiming for $100-$200 million in incremental revenue from high-growth brands by 2027.